Add to ORKGPharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibito
Paolo Verdecchia1, Fabio Angeli1, Giovanni Mazzotta1, Giorgio Gentile2, Gianpaolo Reboldi21Departmen...
Information about reprints can be found online at: Reprints: document. Permissions and Rights Questi...
Helmy M SiragyProfessor of Medicine and Endocrinology, Department of Medicine, Director, Hypertensio...
Ayad K AliDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Flori...
1) Describe the mechanism of action of aliskiren. 2) Determine the appropriate initial and maximum...
The online version of this article, along with updated information and services, is located on th
pharmacovigilance at a tertiary care hospital in Conclusions: The results obtained will contribute t...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
The renin–angiotensin–aldosterone system (RAAS) plays a pivotal role in regulating blood pressure, v...
Aliskiren is a novel oral antihypertensive agent, and the first in the new class of direct renin inh...
Aliskiren is a novel oral antihypertensive agent, and the first in the new class of direct renin inh...
The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathophysiology of arterial ...
Aliskiren (AL) is classified as angiotensin converting enzyme inhibitors (ACEIs) used as antihyperte...
Kalathil K SureshkumarDivision of Nephrology and Hypertension, Allegheny General Hospital, Pittsburg...
Bhatti et al. This is an open access article distributed under the terms of the Creative Commons Att...
Paolo Verdecchia1, Fabio Angeli1, Giovanni Mazzotta1, Giorgio Gentile2, Gianpaolo Reboldi21Departmen...
Information about reprints can be found online at: Reprints: document. Permissions and Rights Questi...
Helmy M SiragyProfessor of Medicine and Endocrinology, Department of Medicine, Director, Hypertensio...
Ayad K AliDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Flori...
1) Describe the mechanism of action of aliskiren. 2) Determine the appropriate initial and maximum...
The online version of this article, along with updated information and services, is located on th
pharmacovigilance at a tertiary care hospital in Conclusions: The results obtained will contribute t...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
The renin–angiotensin–aldosterone system (RAAS) plays a pivotal role in regulating blood pressure, v...
Aliskiren is a novel oral antihypertensive agent, and the first in the new class of direct renin inh...
Aliskiren is a novel oral antihypertensive agent, and the first in the new class of direct renin inh...
The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathophysiology of arterial ...
Aliskiren (AL) is classified as angiotensin converting enzyme inhibitors (ACEIs) used as antihyperte...
Kalathil K SureshkumarDivision of Nephrology and Hypertension, Allegheny General Hospital, Pittsburg...
Bhatti et al. This is an open access article distributed under the terms of the Creative Commons Att...
Paolo Verdecchia1, Fabio Angeli1, Giovanni Mazzotta1, Giorgio Gentile2, Gianpaolo Reboldi21Departmen...
Information about reprints can be found online at: Reprints: document. Permissions and Rights Questi...
Helmy M SiragyProfessor of Medicine and Endocrinology, Department of Medicine, Director, Hypertensio...